Evidence map›Paper›PMID 32656637›Full record

ArticleInternational journal of hematology2020

Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.

Naoyuki Uchida, Kana Matsumoto, Toru Sakura, Michihiro Hidaka, Toshihiro Miyamoto, Tetsuya Eto, Yoshinobu Maeda, Tohru Murayama, Naohito Fujishima, Goichi Yoshimoto and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 1 country.

Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. nuchida@toranomon.gr.jp.ORCID http://orcid.org/0000-0001-5952-5926
Kana MatsumotoDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Toru SakuraDepartment of Hematology, Saiseikai Maebashi Hospital, Gunma, Japan.
Michihiro HidakaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Toshihiro MiyamotoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Tohru MurayamaDepartment of Hematology, Hyogo Cancer Center, Hyogo, Japan.
Naohito FujishimaDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Goichi YoshimotoDepartment of Hematology, National Kyushu Medical Center, Fukuoka, Japan.
Kunihiko MoritaDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Junji KishimotoDepartment of Research and Development of Next Generation Medicine, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.
Shuichi TaniguchiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Takuya YamashitaDivision of Hematology and Oncology, St. Luke's International Hospital, Tokyo, Japan.
Shin-Ichiro MoriDivision of Hematology and Oncology, St. Luke's International Hospital, Tokyo, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Mine HaradaDepartment of Hematology, Karatsu Higashimatsuura Medical Association, Saga, Japan.
Japan Study Group for Cell Therapy, Transplantation (JSCT)
Kyushu University · JPDoshisha Women's College of Liberal Arts · JPSt. Luke's International Hospital · JPToranomon Hospital · JPAkita University · JPGunma Saiseikai Maebashi Hospital · JPHamanomachi Hospital · JPHokkaido University · JPHyogo Prefectural Cancer Center · JPJapan Medical Association · JPKumamoto Medical Center · JPNational Kyushu Medical Center · JPOkayama University · JP

Funding

The Japanese Ministry of Health, Labour and Welfare H22-018
6 · The paper itself

Abstract

An optimal pretransplant conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older adults has not been established. Three prospective multicenter phase II studies were conducted, in which 142 patients older than 54 years (median age, 61 years; range 55-70 years) with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) received a myeloablative dose of intravenous busulfan (ivBu, 12.8 mg/kg) along with fludarabine (180 mg/m

Indexed as

AgedAge FactorsBusulfanClinical Trials, Phase II as TopicDisease-Free SurvivalFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesProspective StudiesRadiation DosageTransplantation ConditioningBusulfanfludarabineVidarabineAllogeneic hematopoietic stem cell transplantationIntravenous busulfanMyeloablative conditioningOlder adults

Identifiers

PMID32656637
OpenAlexW3041644330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.